2 ml of acid phenol were added to the buffered and incubated S. cerevisia cells after transferral of the supernatant to a new tube.

Aiming at finding possible reasons for the discrepancies between our findings and published data could be the amount of ONTAK used in patients, we filed an amendment to the clinical trial allowing the inclusion of additional 4 patients. These patients will receive higher doses (12microg/kg 3x and 18microg/kg 1x) before vaccination. Taking into account direct effects of ONTAK on DC, patients will be vaccinated some days after last ONTAK treatment (as soon as blood DC have recovered to 50% of pre ONTAK amount). Third stage of DERMA-ER-DC 05 clinical trial.

These are RCC patients with clear cell histology, treated using the PME-CD40L DC product. At present, 6 of the 12 patients that have been restaged using RECIST criteria have less tumor burden that when they enrolled in the study (15 weeks earlier).

Monocyte-derived and cocktail-matured DC electroporated with a combination of RNAs encoding tumor antigens (MelanA, Mage3, Survivin) and E/L-selectin are currently used in a clinical trial. Most patients having received the vaccine already demonstrated broad responses to numerous peptides prior vaccination. Significantly enhanced responses to several peptides and occurrence of new responses was seen in 6 patients, 5 of which were vaccinated with E/L-S+ DC. These data provide evidence for a superior immunopotency of E/L-selectin expressing DC.